Viking Therapeutics Competitors and Similar CompaniesClear all

Viking Therapeutics's competitors and similar companies include Lobesity, Apoglyx, MannKind Corporation and Hua Medicine.

	Viking Therapeutics Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of therapies for metabolic and endocrine disorders.	Lobesity Lobesity (also known as Lobesity Investors) is a company engaged in the clinical and commercial development of therapies to treat obesity and related disorders.	Apoglyx Apoglyx is a biotech company developing a small molecule oral therapy for type 2 diabetes patients.	MannKind Corporation MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.	Hua Medicine Hua Medicine (华领医药) is a drug development company.
Founding Date	Founding Date 2012	Founding Date 2015	Founding Date 2015	Founding Date 1991	Founding Date 2011
Type	Type Public	Type Private	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech diabetes drug development	Tags Manufacturing & Industrial biotech therapy	Tags Healthcare biotech diabetes drug development	Tags Healthcare biotech diabetes drug development pharma	Tags Healthcare biotech diabetes drug development pharma
Locations	Locations San Diego, US HQ	Locations Cleveland, US HQ	Locations Malmö, SE HQ Lund, SE	Locations Westlake Village, US HQ Danbury, US	Locations Shanghai, CN HQ Beijing, CN Wuhan, CN Hong Kong, HK
Employees	Employees 2729% increase	Employees 1	Employees 525% increase	Employees 39513% increase	Employees 168
Valuation ($)	Valuation ($) 8.2 b	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 1.9 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $349m (FY, 2025)	Revenue (est.) ¥492.9m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $26.8m (FY, 2025)	Cost of goods ¥180.1m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $322.2m (FY, 2025)	Gross profit ¥1.6b (FY, 2025)
Net income	Net income ($359.6m) (FY, 2025)	Net income N/A	Net income N/A	Net income $5.9m (FY, 2025)	Net income ¥1.1b (FY, 2025)
Funding
Total funding raised	Total funding raised $ 15m	Total funding raised $ 722.5k	Total funding raised N/A	Total funding raised $ 200m	Total funding raised $ 242.4m

For sources of this data, please see the company profile

View Company Profiles

Lobesity

Cleveland, US

Employees

Lobesity (also known as Lobesity Investors) is a company engaged in the clinical and commercial development of therapies to treat obesity and related disorders.

View company

Apoglyx

Malmö, SE

Employees

5↑ 25% increase

Apoglyx is a biotech company developing a small molecule oral therapy for type 2 diabetes patients.

View company

MannKind Corporation

Westlake Village, US

Employees

395↑ 13% increase

MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.